Pharma Compliance: OIG Program Implementation and Development
This meeting is an opportunity for you to hear from experts in legal and compliance issues who will provide the tools necessary to move forward with compliance program development and compliance strategy.
Physician Education vs. Promotion
Pharmaceutical meetings and events have become an integral component of the drug industry's promotional efforts used to gain face time with...
Transparency: A New Voice for Pharma
The upcoming Pharmaceutical Public Relations & Communications Summit will feature many presentations from pharmaceutical communications and PR specialists who will attempt to offer advice...
Labeling / TV DTC Revisited
Drug Labels Question: How many medical and communications experts does it take to write a package insert? Answer: None. That's a legal problem,...
Indication Bloat – The Next DTC Issue
What If There Were No DTC?When I posed this question to members of the PHARMA-MKTING online discussion group it resulted in a flurry of...
Deconstructing Frist on DTC
Last week Senate Majority Leader Bill Frist, (R., Tenn.) shocked the pharma and advertising industries by calling for pharma to ban DTC advertising for...
To Ban or Not to Ban DTC, That is the Question
The pharmaceutical industry must be reeling from the blow just recently delivered by Senate Majority Leader Bill Frist (R-TN) who called upon the drug...
DTC – Best of Times, Worst of Times
Chairman Bob (Bob Ehrlich over at DTC Perspectives), in stiff upper-lip fashion, predicts that the "best is yet to come" for DTC marketers. Au...
Restrict DTC, but Extend the Patent for New Drugs
When the leading Republican member of Congress and a contender for the next president of the United States says it's time for the pharmaceutical industry to 'clean up it's act' and suggests banning DTC advertising of new drugs for 2 years after launch, you know that you are in trouble. Should the industry fight back or 'suffer the slings and arrows of politicians' until it all blows over? If it fights back, how should it fight back?
A Call to Action: A Mea Non Culpa by Big Pharma
A review of the book 'A Call to Action' by Pfizer CEO Dr. Hank McKinnell. This review focuses on the 10 action items McKinnell promulgates. Notwithstanding an Amazon.com review of the book written by Peter Rost -- Pfizer's whistleblowing head of endocrine care marketing unit -- in which McKinnell is described as making 'an impressive mea culpa,' this book is actually a mea non culpa! Find out why..
